Business Wire

Survey: Fewer Than 1 in 3 Companies Ready for May 25 GDPR Deadline

Del

The General Data Protection Regulation (GDPR) compliance deadline looms eight days away, but only 29 percent of companies will be ready, according to a new global survey conducted by ISACA. Conducted last month, ISACA’s GDPR Readiness Survey provides a near-real-time look at readiness levels, top compliance barriers and expected readiness timeframes.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180517005449/en/

Fewer than 1 in 3 companies say they'll be ready for the GDPR compliance deadline next week, accordi ...

Fewer than 1 in 3 companies say they'll be ready for the GDPR compliance deadline next week, according to new research from ISACA. (Graphic: Business Wire)

GDPR, a regulation out of the European Union, impacts entities doing business in or with the EU starting 25 May 2018. Not only are most unprepared for the deadline, but only around half of the companies surveyed (52 percent) expect to be compliant by end-of-year 2018, and 31 percent do not know when they will be fully compliant.

According to ISACA’s research, the top five challenges related to GDPR compliance are:

  1. Data discovery and mapping (59 percent)
  2. Prioritizing GDPR compliance among other business priorities (47 percent)
  3. Organizational education and change programs (45 percent)
  4. Ensuring cross-departmental collaboration and buy-in (42 percent)
  5. Preparation for data subject access or deletion requests (37 percent)

Cost was the seventh-highest concern, at 32 percent. About 27 percent say it will cost under US $1 million to become GDPR compliant, with 15 percent spending $1 million or more. More than half of the business technology professionals surveyed were unsure how much their organizations would be spending.

Among the survey’s most concerning findings is the level of employee education on GDPR and their role in compliance. Only 39 percent of respondents say their organizations’ employees have been educated to a satisfactory level about their responsibilities to maintain GDPR compliance.

“Employee awareness and education are critical components of ongoing GDPR compliance,” said Chris K. Dimitriadis, Ph.D., CISM, CRISC, CISA, past board chair of ISACA and chair of ISACA’s GDPR Working Group. “Awareness of—and commitment to—well-defined security, data management, and privacy policies and procedures clearly need to be an integral part of every organization’s culture, from the top down.”

The good news is that the majority of executive leaders recognize the importance of GDPR and its implications. According to the ISACA data, nearly 7 in 10 respondents (69 percent) believe their organization’s executives have made becoming GDPR-compliant a priority.

Organizations also expect to achieve significant benefits from GDPR compliance. The top three anticipated positive outcomes are:

  1. Greater data security (60 percent)
  2. Improved business reputation (49 percent)
  3. Marrying data security best practices with corporate culture (43 percent)

“One of the most practical and cost-effective ways organizations can support GDPR and other compliance requirements is to help employees understand the business value of the information they deal with on a regular basis,” said Tim Upton, CEO at TITUS, which sponsored ISACA’s survey and research report. “That way, employees become more aware of their responsibilities when it comes to handling and protecting data within the flow of work, providing added value to the ways organizations earn and maintain the trust of customers and employees.”

More information on the survey, including insights from GDPR experts, is available at www.isaca.org/gdpr-readiness-survey.

About ISACA

Nearing its 50th year, ISACA ® (isaca.org) is a global association helping individuals and enterprises achieve the positive potential of technology. ISACA equips professionals with the knowledge, credentials, education and community to advance their careers and transform their organizations.

Twitter: www.twitter.com/ISACANews

Contact information

ISACA
Michelle Micor, +1-847-385-7217
mmicor@isaca.org
Kristen Kessinger, +1-847-660-5512
kkessinger@isaca.org

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Phase 3 Data on Filgotinib in Biologic-Experienced Rheumatoid Arthritis to Be Presented at 2018 ACR/ARHP Annual Meeting20.10.2018 22:30Pressemelding

Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced detailed results from the Phase 3 FINCH 2 clinical trial of filgotinib, an investigational, selective JAK1 inhibitor, in adults with moderately-to-severely active rheumatoid arthritis and prior inadequate response or intolerance to biologic agents. The data, which are being presented as a late-breaking poster at the 2018 American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP) Annual Meeting in Chicago, suggest filgotinib has a potential role in addressing important unmet needs in the treatment of rheumatoid arthritis. Positive efficacy data from FINCH 2 were previously announced in September 2018. The data show statistically significant improvements in the proportion of patients achieving a range of clinical efficacy endpoints, including the proportion of patients achieving American College of Rheumatology 20 percent (ACR20, primary endpoint), 50 percent

Manchester United and True Religion Launch Denim Range19.10.2018 17:37Pressemelding

Manchester United (NYSE:MANU) and luxury denim brand True Religion have collaborated to launch a range of premium club branded denim wear. A first for the club, the new global partnership with the iconic American denim brand will see a range of men’s & women’s co-branded styles go on sale beginning 26th October in the club’s Megastore as well as online via United Direct and truereligion.com & eu.truereligion.com. The exclusive collection features jeans, shirts and jackets, including a highly desirable limited edition denim jacket embroidered with the club’s crest. Fans will have the opportunity to win a selection of clothing from the new range by visiting www.manutd.com/truereligion. Manchester United’s Group Managing Director, Richard Arnold, comments: “True Religion is a well-known, established name in fashion, creating unique designs without compromising on quality. The range we have collaborated on includes the same attention to detail and craftsmanship that has made True Religion

Arch Insurance Announces Strategic Leadership Changes19.10.2018 13:10Pressemelding

Arch Insurance today announced that Matt Shulman will assume the newly created role of CEO, Arch Insurance North America, effective January 1, 2019. In this role, he will lead Arch Insurance’s operations in the United States and Canada. He will report to Nicolas Papadopoulo, Chairman and CEO of Arch Worldwide Insurance Group. Mr. Shulman, who has more than 20 years of experience in the insurance industry, has been with Arch Insurance since 2009 and has served as the President and CEO of Arch Insurance Europe since 2016. “Matt brings significant U.S. and international experience to this role. Under his leadership, together with our senior team, Arch Insurance will continue to enhance our value proposition to our customers through a robust, diversified product portfolio, creative solutions and excellent service,” Mr. Papadopoulo said. Arch Insurance has also created a new organizational structure with three Chief Underwriting Officers (CUO) dedicated to specific lines of business. These

Takeda to Present Results from Phase 3 ALTA-1L Trial Highlighting Intracranial Efficacy of ALUNBRIG® (brigatinib) Versus Crizotinib in First-Line Advanced ALK+ Non-Small Cell Lung Cancer19.10.2018 12:00Pressemelding

Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that intracranial efficacy data from the Phase 3 ALTA-1L (ALK in Lung Cancer Trial of BrigAtinib in 1 st Line) trial showed improved intracranial progression-free survival (PFS) and intracranial objective response rate (ORR) with ALUNBRIG (brigatinib) compared to crizotinib among anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) patients. Data for these secondary endpoints will be presented in a poster discussion at the European Society for Medical Oncology (ESMO) 2018 Congress on Friday, October 19 at 2:00 p.m. CET in Munich, Germany. These results further support ALUNBRIG as a potential treatment for adults with ALK+ locally advanced or metastatic NSCLC who had not received a prior ALK inhibitor. ALUNBRIG is currently not approved as first-line therapy for advanced ALK+ NSCLC. “ALK+ NSCLC often spreads to the brain, so having options that can clearly demonstrate efficacy both in the brain an

Vertex Receives European CHMP Positive Opinion for KALYDECO® (ivacaftor) to Treat Patients With Cystic Fibrosis Aged 12 to <24 months With Certain Mutations in the CFTR Gene19.10.2018 11:54Pressemelding

Vertex Pharmaceuticals (Europe) Limited today announces that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for KALYDECO® (ivacaftor) to include the treatment of people with cystic fibrosis (CF) aged 12 to <24 months who have at least one of the following nine mutations in their cystic fibrosis transmembrane conductance regulator (CFTR) gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. If the European Commission issues a favorable adoption of the EMA CHMP opinion for the extension of indication, ivacaftor will be the first and only medicine approved in Europe to treat the underlying cause of CF in patients aged 12 to <24 months, who have specific mutations in the CFTR gene. “Cystic fibrosis is a chronic, progressive disease that is present at birth, with symptoms often occurring in infancy, so early treatment is crucial to deliver the best possible outcomes for patients,” said Reshma Kewalr

Schlumberger Announces Third-Quarter 2018 Results19.10.2018 11:00Pressemelding

Schlumberger Limited (NYSE: SLB) today reported results for the third quarter of 2018. (Stated in millions, except per share amounts) Three Months Ended Change Sept. 30, 2018 Jun. 30, 2018 Sept. 30, 2017 Sequential Year-on-year Revenue $8,504 $8,303 $7,905 2% 8% Pretax operating income $1,152 $1,094 $1,059 5% 9% Pretax operating margin 13.5% 13.2% 13.4% 36 bps 15 bps Net income - GAAP basis $644 $430 $545 50% 18% Net income, excluding charges & credits* $644 $594 $581 8% 11% Diluted EPS - GAAP basis $0.46 $0.31 $0.39 48% 18% Diluted EPS, excluding charges & credits* $0.46 $0.43 $0.42 7% 10% North America revenue $3,189 $3,139 $2,602 2% 23% International revenue $5,215 $5,065 $5,147 3% 1% North America revenue, excluding Cameron $2,572 $2,546 $2,086 1% 23% International revenue, excluding Cameron $4,559 $4,387 $4,430 4% 3% *These are non-GAAP financial measures. See section below entitled "Charges & Credits" for details. Schlumberger Chairman and CEO Paal Kibsgaard commented, “Our third